{"id":120207,"date":"2021-05-14T07:45:49","date_gmt":"2021-05-14T14:45:49","guid":{"rendered":"http:\/\/69.46.6.243\/?p=120207"},"modified":"2021-05-14T07:45:49","modified_gmt":"2021-05-14T14:45:49","slug":"new-cdc-guidance-says-masks-no-longer-needed-for-vaccinated-adults","status":"publish","type":"post","link":"https:\/\/new.thepinetree.net\/?p=120207","title":{"rendered":"New CDC Guidance Says Masks No Longer Needed for Vaccinated Adults"},"content":{"rendered":"<p>Atlanta, GA&#8230;According to new CDC guidance, fully vaccinated people can stop wearing masks in most settings. To find a vaccine near you go to vaccines.gov.  The full update on the guidance from the CDC is below the video where Dr. Walensky Announces New CDC Mask Guidance.<\/p>\n<p><iframe loading=\"lazy\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/rcejFn22cSs\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>Agency Guidance Review<br \/>\nDATE: March 10, 2021<br \/>\nTO: Rochelle P. Walensky, MD, MPH<br \/>\nDirector, CDC, and Administrator, ATSDR<br \/>\nFROM: Anne Schuchat, MD (RADM, USPHS, Ret.)<br \/>\nPrincipal Deputy Director, CDC<br \/>\nSUBJECT: Summary of Guidance Review<\/p>\n<p>BACKGROUND:<br \/>\nAs part of your pledge to lead an effort to restore the public\u2019s trust in the CDC, you asked me to begin a<br \/>\ncomprehensive review to ensure that all of CDC\u2019s existing guidance related to COVID-19 is evidencebased and free of politics.<\/p>\n<p>In response to the dynamic circumstances of emerging infections and public health emergency<br \/>\nresponses, CDC has customarily issued \u201cinterim\u201d guidance documents that are updated as new<br \/>\ninformation and insights are gained, once novel interventions become available including through<br \/>\nemergency use authorization, or once research reveals greater certainty that permits strengthening or<br \/>\nrejecting earlier interim recommendations. CDC staff have developed thousands of documents during<br \/>\nthe COVID-19 response, including foundational guidance documents that address major areas of<br \/>\nconcern as well as numerous subsidiary tools and resources adapted from the foundational guidance.<br \/>\nAt your request, I led a process to rapidly assess the major or foundational guidance the agency had<br \/>\nissued in order to identify primary documents that needed updating or removal. I also sought to identify<br \/>\npractices that could strengthen the transparency of the evidentiary basis for CDC\u2019s COVID-19 guidance.<br \/>\nIn addition to my own review, I sought review of the process and results from current and former<br \/>\nIncident Managers and Principal Deputy Incident Managers of CDC\u2019s Emergency Response, as well as key<br \/>\nCenter Directors. The review also included a general assessment of the approach to cross-clearance<br \/>\nwithin the Incident Management Structure\u2019s task forces (Appendix 1) as well as how the CDC website<br \/>\nalerts readers to changes in guidance and relationships between the evidence-base and various<br \/>\nguidance documents.<\/p>\n<p>PROCESS<br \/>\nMy review built on processes that were initiated by the CDC\u2019s response leadership toward the end of<br \/>\nlast year. From October 2020 through January 2021, CDC COVID-19 response leadership (I.e., Incident<br \/>\nmanager and Principal Deputy incident managers) reviewed the existing COVID-19 related guidance<br \/>\ndocuments, considerations and supporting communication materials for areas that needed critical<br \/>\nupdates, based on several factors such as the accumulation of new evidence . The response leaders used<br \/>\nan iterative process which involved requesting that each task force lead review guidance involving their<br \/>\narea of expertise, and prioritizing material for major or minor updates as well as documents that should<br \/>\nbe replaced or removed. Building on this work, I gathered additional insights through key informant<br \/>\ninterviews with CDC staff, with iterative input from the IMS leaders, as well as input I received from<br \/>\npublic health stakeholders concerned about the rationale or evidence-base for some guidance.<br \/>\nAgency Guidance Review<\/p>\n<p>General observations: There were a variety of issues identified including a) guidance that was not<br \/>\nprimarily authored by CDC staff; b) reliance on less directive language (e.g., \u2018considerations\u2019) than<br \/>\nresponse leadership felt could be supported by existing evidence; and c) availability of new data or<br \/>\nevolving scientific understanding that necessitated updated recommendations. I also found that some<br \/>\nrecommendations were accompanied by science briefs detailing the evidence-base supporting the<br \/>\nguidance, but these supporting science briefs had not yet consistently been produced and\/or publicly<br \/>\nposted for each major area of guidance. Response leaders told me they had updated internal clearance<br \/>\npractices to have reviewers more systematically challenge authors\u2019 use of phrases like \u2018consider\u2019 or \u2018if<br \/>\nfeasible.\u2019 The response leadership team had developed a new template for guidance documents. The<br \/>\ndocument development and clearance procedures were intended to differentiate between CDC<br \/>\nrecommendations where a sufficiently robust evidence-base existed vs. documents where limited<br \/>\nevidence existed so that the latter could be repackaged as \u201cresources\u201d rather than guidance.<\/p>\n<p>Major findings<br \/>\nGuidance removed: By the time of my review in late January and February 2021, two documents<br \/>\ndeveloped or finalized outside of the agency had already been removed (\u201cThe Importance of Reopening<br \/>\nof America\u2019s Schools this Fall\u201d posted July 23, 2020 \u2013 removed October 29, 2020) or replaced (Overview<br \/>\nof Testing for SARS-COV-2 posted August 24, 2020, replaced September 18, 2020). A link to a third<br \/>\ndocument (\u201cOpening up America Again\u201d which was released on April 16, 2020 through a link posted on<br \/>\nCDC\u2019s web) was removed February 7, 2021 during the process of my review (Table 1).<br \/>\nGuidance updates: The review by the task forces and response leadership identified several areas<br \/>\nwhere they prioritized development of updated guidance because of evolving research and<br \/>\nobservational data from implementation efforts, including: phased prevention linked to epidemiologic<br \/>\nthresholds; K-12 school operational guidance; Institutions of Higher Education guidance; Overview of<br \/>\ntesting guidance linked to more targeted specifications for selected settings (e.g., correctional<br \/>\ninstitutions; non-health care workplaces); duration of exemption from quarantine after natural infection<br \/>\nand after vaccination; mask related guidance (orders such as for Federal property and public corridor<br \/>\nconveyances and updated guidance to incorporate new information on improvement of fit and<br \/>\nfiltration), and travel related guidance including the requirement for laboratory testing pre-departure<br \/>\nfor international arrivals (Table 2). Several of these guidance documents have been recently released<br \/>\n(Table 3) or are expected to complete interagency review, as appropriate, and be completed in the<br \/>\nweeks ahead.<\/p>\n<p>Guidance related to COVID-19 vaccines: Given the rapidly evolving trial data and evidence-base on<br \/>\nvaccines, a number of guidance documents have been developed related to COVID-19 vaccines, vaccine<br \/>\nprioritization, and clinical considerations in conjunction with the FDA\u2019s issuance of emergency use<br \/>\nauthorizations. Multiple recommendations were issued related to vaccines since early December 2020.<br \/>\nThe Advisory Committee on Immunization Practices uses a formal evidence to recommendations<br \/>\nprocess in their reviews and holds public meetings where the evidence is reviewed before deliberation<br \/>\noccurs. This process complements public deliberations carried out by the FDA\u2019s Vaccines and Related<br \/>\nBiological Products Advisory Committee. Despite the transparency and reliance on scientific data<br \/>\nreview, public concerns about vaccine recommendations persist, particularly surrounding prioritization<br \/>\nin the setting of supply constraints. CDC has been committed to updating the interim considerations for<br \/>\nAgency Guidance Review<br \/>\n3<br \/>\nclarity based on ongoing feedback and expanding evidence. These updates have been vetted with<br \/>\ndiverse clinical partners in addition to ACIP members.<br \/>\nEvidence-base: The availability of scientific briefs (Table 4) provides transparency to the evidence-base<br \/>\nthat supports updated or new guidance. While the response typically reviews new evidence in the<br \/>\nprocess of developing guidance and convenes cross-task force deliberations to review the new evidence,<br \/>\nthere was not a consistent practice of publicizing the supporting evidence in a scientific brief in<br \/>\nconjunction with every major new guidance. We are now committed to providing updated science<br \/>\nbriefs if there is research to inform guidance updates (see recommendations).<br \/>\nTransparency and credibility in dissemination of guidance: A major update to landing pages and<br \/>\nformatting of the CDC\u2019s website for COVID-19 was completed during the time period of my review, and<br \/>\nthis has improved usability of the site. While the response had added a search function for COVID-19<br \/>\nguidance documents in July 2020, and the response\u2019s Joint Information Center developed a summary of<br \/>\nguidance documents disseminated to partners on a regular basis, this review suggests that additional<br \/>\nmeasures would enhance accessibility of guidance updates for stakeholders and the public. As I<br \/>\nconducted my review, I found it difficult to a) tell whether a new document represented a major or very<br \/>\nminor update to an existing guidance and b) decipher the core recommendations in long documents.<br \/>\nWhile the version date of previous guidance is noted when updates are posted, the crux of what was<br \/>\nnew or changed was difficult to find. Further, I determined that a thorough executive summary or<br \/>\nabstract highlighting the core features of a guidance document, and a separate \u2018what has changed\u2019<br \/>\nsection would help practitioners quickly incorporate new guidance into their ongoing routines without<br \/>\nhaving to review the entire document. Finally, consumers and the public could be more assured of the<br \/>\nscience-base for guidance if CDC routinely provides scientific briefs, provided a landing spot that listed<br \/>\nall recently updated changes or at a minimum, links to appropriate evidentiary support for major new<br \/>\nguidance and guidance changes. Additional information on CDC\u2019s website describing the general<br \/>\nprocess by which guidance is developed could also support transparency.<br \/>\nNext Steps and Recommendations.<\/p>\n<p>The CDC will finalize production and reviews of remaining prioritized new guidance in the weeks ahead.<br \/>\nIn order to strengthen CDC\u2019s scientific rationale and communication for existing and forthcoming<br \/>\nguidance, I recommend:<br \/>\n1. Use of scientific briefs or lists of supporting evidence for major new guidance documents. These<br \/>\nneed not be exhaustive but should make the scientific rationale for major changes easily<br \/>\naccessible.<br \/>\n2. Support transparency in messaging related to areas where the evidence-base is not sufficiently<br \/>\nstrong or where there are real tradeoffs between theoretic benefits\/risks of a course of action<br \/>\nand practical implementation barriers to a course of action.<br \/>\n3. Routinely include an abstract or executive summary which briefly outlines key components of<br \/>\nnew guidance.<br \/>\nAgency Guidance Review<br \/>\n4. Routinely provide clear summary of what has changed when updates to guidance are posted,<br \/>\nallowing the public to differentiate major from minor changes and the rationale for changes.<br \/>\nIncorporate more consistent use of hyperlinks for \u201creusable elements\u201d (e.g., quarantine period,<br \/>\ndefinition of close contact) that are featured in numerous guidance documents, in order to<br \/>\nassure more systematic updating of all guidance that relies on such concepts which themselves<br \/>\nare occasionally updated.<br \/>\n5. Plan on media and stakeholder briefings when major guidance is issued. This should allow<br \/>\nquestions about changes and the scientific rationale to be addressed promptly. Minor guidance<br \/>\nupdates can be messaged in conjunction with general media briefings, while major guidance<br \/>\nupdates should be accompanied by more complete roll-out plans to address both public and<br \/>\npolicymaker concerns and highlight the science or new knowledge that has led to the changes.<br \/>\n6. Plan to review major guidance areas at least every three months during the COVID-19 response<br \/>\nto assess when further changes are needed.<br \/>\n7. Reduce the number of adaptations of guidance documents that CDC issues. Encourage partner<br \/>\norganizations in collaboration with the CDC to prepare such documents derived from CDC\u2019s<br \/>\nfoundational guidance. This will conserve CDC\u2019s scientific and technical resources for the most<br \/>\nimpactful actions, and permit partners more familiar with each audience to achieve appropriate<br \/>\nlanguage and incorporate real world settings more accurately.<br \/>\n8. To the greatest extent possible, incorporate end user input to guidance products to assure<br \/>\nrecommendations are accessible and easily understood in order to foster accelerated uptake.<br \/>\nAgency Guidance Review<\/p>\n<p>Table1. COVID-19 Guidance Documents Removed from CDC Website<br \/>\nTitle Date Posted Date Removed<br \/>\nThe Importance of Reopening of America\u2019s Schools this Fall July 23, 2020 October 29, 2020<br \/>\nOverview of Testing for SARS-COV-2 August 24, 2020 September 18, 2020<br \/>\nOpening up America Again (link on CDC site) April 16, 2020 February 7, 2021<br \/>\nTable 2. COVID-19 Prioritized Major New or Updated Guidance based on Incident Manager System<br \/>\nLeadership Review, October 2020 through January 2021<br \/>\nTitle Released as of<br \/>\nMarch 8, 2021<br \/>\nRecommendations-Phased Prevention Strategies to Reduce SARS-CoV-2 Transmission1<br \/>\nOperational Strategies for K-12 Schools and Childcare<br \/>\nScientific Brief: Transmission of SARS-CoV-2 in K-12 schools<br \/>\n\uf050<br \/>\n\uf050<br \/>\nOverview of Testing for SARS-CoV-2 Guidance Update<br \/>\nSupporting testing guidance for specific settings:<br \/>\n\u2022 Interim Guidance for SARS-CoV-2 Testing in Correctional and Detention Facilities<br \/>\n\u2022 Guidance-SARS-CoV-2 Testing Strategy for Select Workplaces<br \/>\n\u2022 Updated Guidance-Testing-Screening-Outbreak Response for IHEs<br \/>\n\u2022 Interim Guidance for Health Departments for SARS-CoV-2 Testing in Homeless<br \/>\nShelters and Encampments<br \/>\nDuration of Isolation and Precautions for Adults with COVID-19 \uf050<br \/>\nMasking Guidance:<br \/>\n\u2022 Federal property<br \/>\n\u2022 Public conveyances<br \/>\n\u2022 Fit and Increase the Filtration<br \/>\n\uf050<br \/>\n\uf050<br \/>\n\uf050<br \/>\nCDC Guidance for Promoting COVID-19 Safety in Domestic and International Travel for<br \/>\nSea Travel<br \/>\n\uf050<br \/>\nCOVID-19 Critical Infrastructure Sector Response Planning \uf050<br \/>\n1 Prioritized in Fall 2020. Deprioritized guidance in the context of scaling vaccination. Continuing to assemble<br \/>\nevidence-base for high risk settings.<br \/>\nAgency Guidance Review<br \/>\n6<br \/>\nTable 3. COVID-19 Major Guidance Documents Released or Updated since January 20, 2021 as of<br \/>\nMarch 8, 2021<br \/>\nDate Released Title<br \/>\n3\/8\/21 Interim Public Health Recommendations for Fully Vaccinated People<br \/>\nThis is the first set of public health recommendations for fully vaccinated people.<br \/>\n2\/16\/21 Return to Work Criteria for Healthcare Personnel with SARS-CoV-2 Infection (Interim<br \/>\nGuidance)<br \/>\nChanges to more closely align guidance with updates to the Decision Memo:<br \/>\nHCP who are severely immunocompromised, could remain infectious more than 20<br \/>\ndays after symptom onset. Consultation with infectious diseases specialists is<br \/>\nrecommended; use of a test-based strategy for determining when these HCP may<br \/>\nreturn to work could be considered.<br \/>\n2\/16\/21 Discontinuation of Transmission-Based Precautions and Disposition of Patients with<br \/>\nSARS-CoV-2 Infection in Healthcare Settings<br \/>\nChanges to more closely align guidance with updates to the Decision Memo:<br \/>\n\u2022 Patients who are severely immunocompromised could remain infectious<br \/>\nmore than 20 days after symptom onset. Consultation with infectious<br \/>\ndiseases specialists is recommended; use of a test-based strategy for<br \/>\ndetermining when to discontinue Transmission-Based Precautions could be<br \/>\nconsidered.<br \/>\n2\/16\/21 Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus<br \/>\nDisease (COVID-19)<br \/>\n\u2022 New information on potential for under-detection of occult hypoxemia by<br \/>\npulse oximetry, especially among persons with dark skin<br \/>\n\u2022 New information on dermatologic manifestations associated with COVID-19<br \/>\n\u2022 New information on prolonged shedding of replication-competent SARSCoV-2 in severely immunocompromised persons<br \/>\n\u2022 New information on reports of reinfection with variant viruses<br \/>\n2\/12\/21 Operational Strategy for K-12 Schools through Phased Mitigation<br \/>\nUpdated to incorporate the best available evidence at this time. The indicators and<br \/>\nthresholds in the operational strategy replace the core indicators in the Indicators<br \/>\nfor Dynamic School Decision-Making.<br \/>\n2\/10\/21 Maximizing Fit for Cloth and Medical Procedure Masks to Improve Performance and<br \/>\nReduce SARS-CoV-2 Transmission and Exposure, 2021<br \/>\nAdded new evidence on two ways of improving the fit of medical procedure masks:<br \/>\nfitting a cloth mask over a medical procedure mask, and knotting the ear loops of a<br \/>\nmedical procedure mask and then tucking in and flattening the extra material close<br \/>\nto the face. Each modification substantially improved source control and reduced<br \/>\nwearer exposure.<br \/>\n2\/5\/21 Requirement for Proof of Negative COVID-19 Test or Recovery from COVID-19 for All<br \/>\nAir Passengers Arriving in the United States<br \/>\nUpdated to include Order<br \/>\n2\/4\/21 Requirement for Face Masks on Public Transportation Conveyances and at<br \/>\nTransportation Hubs<br \/>\nUpdated to include Order<br \/>\nAgency Guidance Review<br \/>\n7<br \/>\nTable 4. COVID-19 Science Briefs Containing Evidence-Base in Support of Updated Guidance<br \/>\nCategory Title Date Updated<br \/>\nPotential Airborne<br \/>\nTransmission<br \/>\nScience Brief: SARS-CoV-2 and Potential Airborne Transmission 10\/5\/20<br \/>\nUse of Cloth Masks Science Brief: Community Use of Cloth Masks to Control the<br \/>\nSpread of SARS-CoV-2<br \/>\n11\/20\/20<br \/>\nOptions to reduce<br \/>\nQuarantine<br \/>\nScience Brief: Options to Reduce Quarantine for Contacts of<br \/>\nPersons with SARS-CoV-2 Infection Using Symptom Monitoring<br \/>\nand Diagnostic Testing | CDC<br \/>\n12\/2\/20<br \/>\nVaccine Allocation The Advisory Committee on Immunization Practices\u2019 Interim<br \/>\nRecommendation for Allocating Initial Supplies of COVID-19<br \/>\nVaccine \u2014 United States, 2020<br \/>\n12\/3\/20<br \/>\nMitigation Summary of Guidance for Public Health Strategies to Address High<br \/>\nLevels of Community Transmission of SARS-CoV-2 and Related<br \/>\nDeaths, December 2020<br \/>\n12\/11\/20<br \/>\nPfizer COVID-19<br \/>\nVaccine<br \/>\nGrading of Recommendations, Assessment, Development, and<br \/>\nEvaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine<br \/>\n12\/13\/20<br \/>\nModerna COVID19 Vaccine<br \/>\nGrading of Recommendations, Assessment, Development, and<br \/>\nEvaluation (GRADE): Moderna COVID-19 Vaccine<br \/>\n12\/20\/20<br \/>\nEvidence for<br \/>\nVaccine Allocation<br \/>\nEvidence Table for COVID-19 Vaccines Allocation in Phases 1b and<br \/>\n1c of the Vaccination Program<br \/>\n12\/20\/20<br \/>\nEmerging SARSCoV-2 Variants<br \/>\nScience Brief: Emerging SARS-CoV-2 Variants | CDC 1\/28\/21<br \/>\nTransmission of<br \/>\nSARS-CoV-2 in K-12<br \/>\nschools<br \/>\nScience Brief: Transmission of SARS-CoV-2 in K-12 schools 2\/12\/21<br \/>\nDuration of<br \/>\nIsolation and<br \/>\nPrecautions for<br \/>\nAdults with<br \/>\nCOVID-19<br \/>\nInterim Guidance on Duration of Isolation and Precautions for<br \/>\nAdults with COVID-19<br \/>\n2\/13\/21<br \/>\nJanssen COVID-19<br \/>\nVaccine<br \/>\nGrading of Recommendations, Assessment, Development, and<br \/>\nEvaluation (GRADE): Janssen COVID-19 Vaccine<br \/>\n3\/1\/21<br \/>\nFully vaccinated<br \/>\nPeople<br \/>\nScience Brief: Background Rationale and Evidence for Public Health<br \/>\nRecommendations for Fully Vaccinated People<br \/>\n3\/8\/21<br \/>\nAgency Guidance Review<br \/>\n8<br \/>\nAppendix 1: Task Forces within CDC\u2019s COVID-19 Incident Management Structure, March 2021<br \/>\nTask Force Name<br \/>\nEpidemiology &#038; Surveillance<br \/>\nData, Analytics &#038; Visualizations<br \/>\nLaboratory &#038; Testing<br \/>\nGlobal Migration<br \/>\nState, Territorial, Local, Tribal (STLT) Support<br \/>\nInternational<br \/>\nCommunity Interventions &#038; Critical Populations<br \/>\nHealth Systems &#038; Worker Safety<br \/>\nVaccine <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atlanta, GA&#8230;According to new CDC guidance, fully vaccinated people can stop wearing masks in most settings. To find a vaccine near you go to vaccines.gov. The full update on the guidance from the CDC is below the video where Dr. Walensky Announces New CDC Mask Guidance. Agency Guidance Review DATE: March 10, 2021 TO: Rochelle [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":120209,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_cbd_carousel_blocks":"[]","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[20,5,33,1],"tags":[],"class_list":["post-120207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-government","category-health-fitness","category-news","last_archivepost"],"jetpack_featured_media_url":"https:\/\/new.thepinetree.net\/wp-content\/uploads\/2021\/05\/Fullscreen-capture-5142021-74107-AM.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/posts\/120207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=120207"}],"version-history":[{"count":0,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/posts\/120207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=\/wp\/v2\/media\/120209"}],"wp:attachment":[{"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=120207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=120207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.thepinetree.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=120207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}